The AACR Annual Meeting serves as a centerpiece of the global cancer research community, bringing together leading experts in the field from all over the world. The conference provides a platform for sharing the latest discoveries and advances in cancer science and medicine across a wide range of topics, from population science and prevention, to cancer biology, translational and clinical studies, as well as survivorship and advocacy. The upcoming AACR 2023 Conference is scheduled to take place from April 14 to 19 in Orlando, Florida, and is set to showcase the exceptional work of top minds in cancer research hailing from various institutions worldwide.
AACR has released the abstracts for its upcoming conference on March 14, 2022. Ferma.AI has analyzed all 8,230 abstracts to identify the most relevant and highly anticipated sessions that are likely to draw the greatest interest among attendees.
Want to improve your conference coverage with Ferma.AI? Schedule a demo to learn how to enhance insights and velocity while reducing costs by 40%.
Highly Anticipated Sessions, by Therapeutic Area
- KEYNOTE-942, Moderna & Merck (Abstract)
- KEYMAKER-UO2, Merck (Abstract)
- STARBOARD, Genesis Pharma & Pfizer (Abstract)
- REDIRECT, Affimed (Abstract)
- BRUIN, Eli LIlly (Abstract)
- MMRF MyCheckpoint, Bristol-Myers Squibb (Abstract)
Non-Small Cell Lung Cancer (NSCLC)
- CHRYSALIS-2, Janssen (Abstract)
- HERTHENA-Lung02, Daiichi Sankyo (Abstract)
- HUDSON, AstraZeneca (Abstract)
Highly Anticipated Sessions in Melanoma
- A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open- label Phase 2 mRNA-4157-P201/Keynote-942 trial
KEYNOTE-942 | NCT03897881 | Moderna and Merck | Abstract | Late-Breaking Session
One of the highly anticipated Late-breaking sessions at AACR 2023 focuses on the KEYNOTE-942 trial, jointly conducted by Moderna and Merck. This study aims to evaluate the efficacy of postoperative adjuvant therapy with mRNA-4157 and pembrolizumab, in comparison to pembrolizumab alone, in patients with cutaneous melanoma who have undergone complete resection and are at a high risk of recurrence. The focus of this trial is to assess the potential improvement in recurrence-free survival (RFS) for participants who receive the combination therapy.
KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
KEYMAKER-U02 | NCT04303169 | Merck | Abstract | Late-Breaking Session
Merck's KEYMAKER-U02 study is designed to evaluate the safety and efficacy of pembrolizumab, either alone or in combination with investigational agents, in patients with stage III melanoma who are eligible for neoadjuvant therapy. The trial aims to determine the potential benefits of pembrolizumab in improving patient outcomes, and the focus will be on assessing the safety profile and efficacy of the drug in this population.
Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma
STARBOARD | NCT04657991 | Genesis Pharma and Pfizer | Abstract | Late-Breaking Session
The STARBOARD study is conducted by Genesis Pharma and Pfizer to evaluate the safety and efficacy of a combination of encorafenib, binimetinib, and pembrolizumab, for the treatment of advanced or metastatic melanoma with BRAF V600 mutation that has not received prior treatment. The study aims to determine if the combination of these three drugs can provide better outcomes for patients compared to current standard-of-care treatments.
Highly Anticipated Sessions in Hematological Malignancies
REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)
REDIRECT | NCT04101331 | Affimed | Abstract | Late-Breaking Session
REDIRECT Study by Affimed is a phase II study to evaluate the safety and effectiveness of AFM13, an investigational medication, as a standalone treatment for CD30-positive T-cell lymphoma. AFM13 is a bispecific chimeric antibody that targets both CD30 and CD16A proteins and is designed to treat malignancies that have CD30 overexpression. The aim of the study is to evaluate the potential of AFM13 in treating CD30-positive malignancies and determine its safety profile. The results of this study may pave the way for the development of a new treatment for patients with CD30-positive T-cell lymphoma.
Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
BRUIN | NCT03740529 | Eli Lilly | Abstract | Late-Breaking Session
Eli Lilly is conducting the open-label BRUIN study, a Phase 1/2 trial that aims to evaluate the safety and efficacy of LOXO-305 (pirtobrutinib), an oral medication, in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL) who have either not responded to standard treatments or cannot tolerate them.
Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial
MMRF MyCheckpoint | NCT04150965 | Bristol-Myers Squibb | Abstract | Late-Breaking Session
MMRF MyCheckpoint study by Bristol-Myers Squibb is a Phase 1/2 randomized trial for patients with relapsed refractory Multiple Myeloma. The study focuses on patients who have experienced relapse after treatment with prior therapies. The aim of the study is to evaluate the immunological effects and safety of two agents, Anti-LAG-3 and Anti-TIGIT, both as single agents and in combination with pomalidomide and dexamethasone. Patients will be randomly assigned to either the Anti-LAG-3 or Anti-TIGIT treatment arm and will receive treatment with the assigned agent for one cycle as a single agent. Subsequently, pomalidomide and dexamethasone will be added to the treatment for subsequent cycles. The study seeks to gain insights into the effectiveness and safety of these treatments
Highly Anticipated Sessions in Non-Small Cell Lung Cancer (NSCLC)
Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)
CHRYSALIS-2 | NCT04077463 | Janssen | Abstract | Poster Session
Janssen's CHRYSALIS-2 study is generating excitement among the audience. Study has evaluated ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib in EGFR-mutant NSCLC patients after osimertinib and platinum-based chemotherapy. The study found an ORR of 29% and 26% in EGFR/MET-dependent and independent patients, respectively, with a 39% ORR in patients with an unknown resistance mechanism.
HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor
HERTHENA-Lung02 | NCT05338970 | Daiichi Sankyo | Abstract | Late-Breaking Session
During the conference, Daiichi Sankyo will present the HERTHENA-Lung02 study which aims to compare the efficacy of patritumab deruxtecan versus platinum-based chemotherapy in participants with advanced NSCLC with an EGFR-activating mutation. The study's primary objective is to measure progression-free survival and secondary endpoint of overall survival in patients who have previously failed third-generation EGFR TKI therapy.
Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment
HUDSON | NCT03334617 | AstraZeneca | Abstract | Late-Breaking Session
The HUDSON Study by Astrazeneca is investigating the immunomodulatory effects of ceralasertib in combination with durvalumab in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. It is an open-label, multi-centre, umbrella Phase II study designed to assess the efficacy, safety, and tolerability of multiple treatment arms for patients in need of novel therapies after receiving immune checkpoint inhibitors and platinum-doublet therapies.
Note: All the summaries of the Late-breaking sessions in the blog are based on clinicaltrial.gov, and not the abstracts (yet to be released).
Future Perspectives Ferma.AI tracks abstract and data releases for all major healthcare conferences, alongside social media and healthcare news reactions. Interested in learning more about how Ferma.AI can enhance your conference coverage and insights while also reducing costs by 40%?
Schedule a brief call with us to see a live demonstration.